Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brostallicin - CTI BioPharma

Next Previous
Drug Profile

Brostallicin - CTI BioPharma

Alternative Names: PNU-166196; PNU-166196A; SMi-BX1

Latest Information Update: 28 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacia Corporation
  • Developer CTI BioPharma; National Cancer Institute (USA); Systems Medicine
  • Class Antineoplastics; DNA-binding proteins; Guanidines; Pyrroles; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Soft tissue sarcoma; Triple negative breast cancer

Most Recent Events

  • 26 Jun 2023 TI BioPharma has been acquired by Swedish Orphan Biovitrum
  • 30 May 2014 Cell Therapeutics is now called CTI BioPharma
  • 01 Jun 2013 Final efficacy data from a Phase-II trial in Breast cancer (Metastatic disease, Combination therapy) presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO-2013)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top